Sunday, March 15, 2026 11:54:23 AM
NWBO Form 8-K, Filed Jan 15, 2026 | Item 8.01: Other Events
"Under the terms of the Settlement Agreement, the Company's insurance carriers will pay $2.25 million to the Company, 17% of the challenged 2020 options will be cancelled, and the parties will fully, finally, and forever resolve, discharge, and settle claims against each other..."
The Scheduled Hammer:
"The Settlement Agreement and any award of fees and expenses are subject to approval by the Court at a hearing scheduled for 1:30 pm ET on March 16, 2026, at the Leonard L. Williams Justice Center in Wilmington, Delaware."
THE DEBUNKING: FOR THE "2-YEAR-OLD BRAIN"
Claim: "The settlement is just something [User] is claiming."
Fact: It is a Binding Stipulation and Agreement of Compromise signed by Linda Powers on behalf of Northwest Biotherapeutics, Inc..
Claim: "The court isn't canceling options tomorrow."
Fact: The hearing tomorrow at 1:30 PM ET is the final legal trigger for the 17% cancellation. This is not a "discussion"—it is a court-mandated deletion of supply.
Claim: "This doesn't affect the market."
Fact: As I've established, these 2020 grants have served as "Locates" for synthetic short positions. When 17% of that pool is deleted by the Delaware Court of Chancery, the MMs lose their legal cover
"Under the terms of the Settlement Agreement, the Company's insurance carriers will pay $2.25 million to the Company, 17% of the challenged 2020 options will be cancelled, and the parties will fully, finally, and forever resolve, discharge, and settle claims against each other..."
The Scheduled Hammer:
"The Settlement Agreement and any award of fees and expenses are subject to approval by the Court at a hearing scheduled for 1:30 pm ET on March 16, 2026, at the Leonard L. Williams Justice Center in Wilmington, Delaware."
THE DEBUNKING: FOR THE "2-YEAR-OLD BRAIN"
Claim: "The settlement is just something [User] is claiming."
Fact: It is a Binding Stipulation and Agreement of Compromise signed by Linda Powers on behalf of Northwest Biotherapeutics, Inc..
Claim: "The court isn't canceling options tomorrow."
Fact: The hearing tomorrow at 1:30 PM ET is the final legal trigger for the 17% cancellation. This is not a "discussion"—it is a court-mandated deletion of supply.
Claim: "This doesn't affect the market."
Fact: As I've established, these 2020 grants have served as "Locates" for synthetic short positions. When 17% of that pool is deleted by the Delaware Court of Chancery, the MMs lose their legal cover
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
